Apert and Crouzon syndromes are well known craniostenosis. In the last 10 years several studies were performed to provide a better understanding of the etiology and pathogenesis of these diseases. Both have an autosomal dominant mode of transmission, and a mutation in the gene encoding for the fibroblast growth factor receptor 2 (FGFR2) is the cause in most patients. However, the fact that the same mutation can produce a wide range of phenotypic expression makes the mechanism of anomalous development more complex. The extracellular matrix (ECM) is composed of proteins, glycosaminoglycans, and cytokines that are secreted in an autocrine and paracrine manner and are able to modify the ECM. Fibroblast growth factors are complexed with heparan sulfate, a component of the ECM, before binding the FGFR2. Data exist about different expressions of cytokines and ECM macromolecule in craniostenosis-derived fibroblasts and osteoblasts. Changes in ECM composition could explain the altered osteogenic process and account for pathologic variations in cranial development in addition to the FGFR2 mutations.
T he craniosynostoses are a heterogeneous group of syndromes characterized by a premature sutural fusion that may occur alone or together with other anomalies. More than 70 syndromes are described.
Apert and Crouzon syndromes are well-known craniostenoses. In the last 10 years, several studies have been done to provide a better understanding of the etiology and pathogenesis of these diseases.
Both have an autosomal dominant mode of transmission, and a mutation in the gene encoding for the fibroblast growth factor receptors 2 (FGFR2) is the cause in most patients. However, the fact that the same mutation can produce a wide range of phenotypic expression makes the mechanism of anomalous development more complex.
The regulatory processes that underline ossification and fusion of the sutures during skull morphogenesis are dependent on the conditions of the extracellular microenvironment. The extracellular matrix (ECM) is composed of proteins, glycosaminoglycans, and cytokines that are secreted in an autocrine and paracrine manner and are able to modify the ECM. Fibroblast growth factors (FGFs) are complexed with heparan sulfate, a component of the ECM, before binding the FGFR2. Data exist about different expressions of cytokines and ECM macromolecules in craniostenosis-derived fibroblasts and osteoblasts. In this scenario, FGFR2 and ligands act.
In the current review we summarize some recent developments in the etiology and pathogenesis of Apert and Crouzon syndromes.
APERT SYNDROME Clinical Findings I n 1906, Apert 1,2 defined a syndrome characterized by skull and midfacial malformations and syndactyly of the hands and feet of a special type (complete distal fusion with a tendency to fusion also of the bony structures). The hand, when all the fingers are webbed, has been compared with a spoon and, when the thumb is free, to an obstetric hand. In 1960, Blank 3 distinguished two clinical categories: (1) ''typical'' acrocephalosyndactyly, to which the Apert name is appropriately applied, and (2) other forms, lumped together as ''atypical'' acrocephalosyndactyly. The feature distinguishing the 2 types is a middigital hand mass with a single nail common to digits 2-4, found in Apert syndrome and lacking in the others.
Acrobrachycephaly is present, and bulging at the bregma may be noted in some cases. The anterior cranial fossa is very short with consequent shallow orbits and orbital hypertelorism. The middle third of the face is retruded and hypoplastic, resulting in relative mandibular prognatism. The nasal bridge is depressed, and hypertelorism, proptosis, and downslanting palpebral fissures are observed. The lips frequently assume a trapezoid configuration. The palate is highly arched, and cleft of the soft palate is observed in 30% of the cases. Class III malocclusion is present with an anterior open bite, as well as anterior and posterior crossbite. 4 Varying degrees of mental deficiency are associated with the syndrome; however, individuals with normal intelligence have been reported. 5 Cohen and Kreiborg 6 had information on 30 patients with malformations of the corpus callosum, the limbic structures, or both. The authors suggested that these malformations may be responsible for mental retardation. In reviewing their series of 70 children with Apert syndrome, Reiner et al 7 found an IQ greater than 70 in 50% of the children who had a skull decompression before 1 year of age versus only 7.1% in those operated on later in life. Malformations of the corpus callosum and ventricular size did not correlate with the final IQ, whereas anomalies of the septum pellucidum did. The third significant factor in intellectual achievement was the setting in which the children were raised. Only 12.5% of institutionalized children had a normal IQ, whereas 39.3% of those living with their families had a normal IQ. Kreiborg et al 8 described fusion of cervical vertebrae in 68% of patients with Apert syndrome: single fusion in 37% and multiple fusions in 31%. C5-C6 fusion was most common. In contrast, cervical fusion occurs in 25% of patients with Crouzon syndrome and most commonly involves C2-C3 only. The authors concluded that when fusions are present, C5-C6 involvement in the Apert syndrome and C2-C3 involvement in Crouzon syndrome separate the two conditions in most cases.
Cohen and Kreiborg 9 commented on the cutaneous manifestations in a series of 136 cases of Apert syndrome. Hyperhidrosis was found in all patients. At adolescence and thereafter the skin was oily. Acneform lesions were particularly prevalent on the face, chest, back, and upper arms. In 1933 Vogt 10 described cases presenting the hand and foot malformations characteristic of Apert syndrome, together with the facial characteristics of Crouzon syndrome, caused by a very hypoplastic maxilla. The syndactyly was less severe than in Apert syndrome and the thumbs and little fingers were usually free. Later, Nager and de Reynier 11 gave this deformity the name of Vogt cephalodactyly, while other authors called it Apert-Crouzon disease, indicating the similarity in both abnormalities.
Genes
Apert syndrome results from mutations in the gene encoding fibroblast growth factor receptor-2 (FGFR2). 12 The FGF receptors comprise a family of related but individually distinct tyrosine kinase receptors. They have a similar protein structure, with three immunoglobulin-like (Ig) domains in the extracellular region, a single membrane spanning segment, and a cytoplasmic tyrosine kinase domain. The FGF receptors that have been identified are FGFR1 (which is mutant in Pfeiffer syndrome), FGFR2 (which is mutant in Apert and Crouzon syndromes), FGFR3 (which is mutant in achondroplasia and Crouzon with acanthosis nigricans), and FGFR4. Sequence analysis of the human FGFR2 gene shows an open reading frame encoding the typical membranespanning, tyrosine kinase receptor structure of the FGFR gene family. Two alternative gene products have been characterized: keratinocyte growth factor receptor (KGFR) and bacterially expressed kinase (BEK). These two isoforms are identical except for a 49-amino acid sequence spanning the second half of the third Ig loop in the extracellular region. This local diversity is caused by the presence of alternative exons within FGFR2, exon B being expressed in the BEK product and exon K26 in KGFR. 13 The variation in expressed gene product is highly significant because they have different patterns of expression in murine embryogenesis. Whereas KGFR appears to have a role in skin development, BEK is preferentially expressed in osteogenesis. BEK transcripts are concentrated in the frontal bones, maxilla, mandibula, and ossicles of the middle ear.
In 1995 Wilkie et al 12 found mutations in the FGFR2 gene. In all unrelated cases of Apert syndrome studied, they identified specific missense substitutions involving adjacent amino acids (ser252-to-trp and pro253-to-arg) in the linker between the second and third extracellular immunoglobulin domains of THE JOURNAL OF CRANIOFACIAL SURGERY / VOLUME 16, NUMBER 3 May 2005 FGFR2. The first of these mutations was caused by a C-to-G transversion at position 934 of the cDNA. The second was caused by a C-to-G transversion at position 937. Later, Slaney et al 14 found differential effects of the two FGFR2 mutations on syndactyly and cleft palate. Among 70 unrelated patients with Apert syndrome, 45 had the S252W mutation and 25 had the P253R mutation. The syndactyly in both the hands and the feet was more severe with the P253R mutation. In contrast, cleft palate was significantly more common in the patients with the S252W mutation.
Oldridge et al 15 stated that recurrent mutations of a serine-proline dipeptide (either ser252 to trp or pro253 to arg) had been identified in more than 160 unrelated individuals with Apert syndrome. They identified three novel mutations of this dipeptide associated with distinct phenotypes. The substitution ser252leu was demonstrated in a boy with mild Crouzon syndrome and also was present in three clinically normal members of his family. A CG-to-TT mutation that predicted a ser252-to-phe substitution resulted in a phenotype consistent with Apert syndrome. Finally, a CGC-to-TCT mutation that predicted a double amino acid substitution (ser252 to phe and pro253 to ser) caused a Pfeiffer syndrome variant with mild craniosynostosis, broad thumbs and big toes, fixed extension of several digits, and only minimal cutaneous syndactyly. The observation that the ser252-to-phe mutation causes Apert syndrome, whereas the other single or double substitutions are associated with milder or normal phenotypes, highlighted the exquisitely specific molecular pathogenesis of the limb and craniofacial abnormalities associated with Apert syndrome. The authors stated that the substitution ser252 to phe was the first noncanonical mutation to be identified in Apert syndrome, its rarity being explained by the requirement for two residues of the serine codon to be mutated. The authors had previously demonstrated exclusive paternal origin of mutation in Apert syndrome in 57 of 57 cases, and suggested that the high apparent rates for several FGFR mutations could arise by a selective advantage conferred to the mutated male germ cell. 16 Consistent with this, there is evidence that the FGF/FGFR signaling pathway plays an important role in the initiation and maintenance of spermatogenesis. 17 In 1999, Oldridge et al 18 studied 260 unrelated patients with Apert syndrome and found that 258 had missense mutations in exon 7 of FGFR2, which affected a dipeptide in the linker region between the second and third immunoglobulin-like domains. Thus, the molecular mechanism of Apert syndrome is exquisitely specific. The authors found that the remaining two patients had Alu-element insertions in or near exon 9. Studies of fibroblasts showed ectopic expression of the KGFR domain of FGFR2, which correlated with the severity of limb abnormalities. This correlation provided the first genetic evidence that signaling through KGFR causes syndactyly in Apert syndrome.
Lajeunie et al 19 screened 36 patients with Apert syndrome for mutations in the FGFR2 gene. Despite the limited genotypic variability in Apert syndrome, contrasting sharply with a wide range of mutations in Crouzon and Pfeiffer syndromes, considerable clinical variability was observed. Two patients had no clinical or radiologic evidence of craniosynostosis. In two other patients with atypical forms of syndactyly and cranial abnormalities, the detection of a specific mutation was helpful in making the diagnosis. The fact that mutations found in patients with Apert syndrome usually are confined to a specific region of the FGFR2 exon IIIa may be useful in making a diagnosis and allowing genetic counseling in difficult cases.
A genotype-phenotype correlation was made by von Gernet et al 20 regarding postoperative craniofacial appearance and degree of syndactyly in 21 patients with Apert syndrome who underwent craniofacial surgery. The craniofacial appearance after craniofacial surgery was better in patients with the P253R mutation, whereas these patients showed a more pronounced severity of the syndactyly.
Apert syndrome is commonly accompanied by acne. Munro and Wilkie 21 studied a patient who was well except for acne, which was present in the pattern described by Blaschko. 22 In this pattern, abnormality of the skin is limited to a linear or whirled pattern. Commonly misinterpreted as dermatomal, the pattern, and therefore the mechanism, is quite distinct. This was interpreted by Shuster 23 as representing the clonal pattern of movement of cells during development. Munro and Wilkie 21 reasoned that if a germline defect in FGFR2 causes acne in the context of Apert syndrome, a mutation confined to epidermal cells (because it had arisen during development) might produce acne in the pattern described by Blaschko. They showed that one of the common FGFR2 mutations in Apert syndrome, a ser252-to-trp substitution, is present in the abnormal, but not the normal, skin.
Anderson et al 24 studied the kinetics of ligand and receptors. They found that Apert syndrome arises as a result of increased affinity of mutant receptors for specific FGF ligands. Yu et al 25 demonstrated that the mutations in two adjacent amino acid residues that cause Apert syndrome, S252W and P253R, break one of the cardinal rules governing ligand specificity of FGFR2. The S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and APERT AND CROUZON SYNDROMES / Carinci et al the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9. The authors demonstrated loss of ligand specificity of FGFR2 and that the severe phenotypes of Apert syndrome likely result from ectopic ligand-dependent activation of FGFR2.
Cells and Extracellular Matrix
It is well known that during embryonic development, variations in the composition of the extracellular matrix (ECM) macromolecules influence bone tissue differentiation. To verify the possible role of cytokines and ECM components as further variables in the onset of phenotype of Apert syndrome, a series of experiments was performed.
In 1997 Bodo et al 26 presented data on the in vitro phenotypic expression of periosteal fibroblasts obtained from patients with Apert syndrome and the effects that interleukins (ILs) induce on the phenotype. Apert fibroblasts synthesized greater quantities of glycosaminoglycans (GAGs). The amount of hyaluronic acid (HA) secreted by Apert fibroblasts was much higher than that secreted by normal fibroblasts, but because the absolute values of heparan sulphate (HS), chondroitin sulphate (CS), and dermatan sulphate (DS) also rose in Apert media, the HA-sulphated GAG ratio was similar in the media obtained from both populations. Both IL-1 and IL-6 triggered elevations of HA in normal cells, although relative percentage secretion remained unaltered but significantly reduced HA secretion by Apert cells. IL-1 significantly increased CS in normal and Apert media, whereas IL-6 enhanced HS and DS in media of both populations. The HA-sulphated GAG ratio decreased in Apert media after IL treatment. So a modification of the extracellular compartment was established.
Subsequently, Bodo et al 27 studied whether the pattern of ILs secreted into the medium by Apert fibroblasts is comparable to that of normal fibroblasts. The levels of IL-1 and IL-6 were lower in Apert than in normal media, whereas levels of IL-1 receptor antagonist (IL-1ra), the natural inhibitor of IL-1, were markedly higher. They also provided evidence that active transforming growth factor beta 1 (TGF-B1), an IL-1 antagonist, was not secreted in greater amount in Apert media with respect to normals. The observed imbalance in the production of ILs suggests that ILs may be the natural autocrine regulators of ECM production in Apert fibroblasts.
In 1999, Locci et al 28 analyzed the accumulation of macromolecules in the ECM of Apert osteoblasts. Apert osteoblasts increase type I collagen, fibronectin, and GAGs secretion compared with normal osteoblasts. Because the ECM macromolecule accumulation is greatly modulated by TGF-B1, they examined the ability of normal and Apert osteoblasts to secrete TGF-B1. The level of the active TGF-B1 isoform was higher in Apert than in normal media. The level of TGF-B1 was decreased by the addition of basic FGF. So a correlation among FGF, TGF-B1, Ils, and ECM was demonstrated.
Lomri et al 29 studied proliferation and differentiation of calvaria cells derived from infants and fetuses with Apert syndrome and FGFR2 mutations. Histologic analysis revealed premature ossification, increased extent of subperiosteal bone formation, and alkaline phosphatase-positive preosteoblastic cells in Apert fetal calvaria compared with agematched controls. Preosteoblastic calvaria cells isolated from infants and fetuses with Apert syndrome showed normal cell growth in basal conditions or in response to exogenous FGF2. In contrast, the number of alkaline phosphatase-positive calvaria cells was fourfold higher than normal in mutant fetal calvaria cells, with the most frequent Apert mutation, S252W, suggesting increased maturation rate of cells in the osteoblastic lineage. These results showed that Apert FGFR2 mutations lead to an increase in the number of precursor cells that enter the osteogenic pathway, leading ultimately to increased subperiosteal bone matrix formation and premature calvaria ossification during fetal development.
Finally, Pellegrini et al 30 reported the crystal structure of the FGFR2 ectodomain in a dimeric form that is induced by simultaneous binding to FGF1 and a heparin decasaccharide. The complex is assembled around a central heparin molecule linking 2 FGF1 ligands into a dimer that bridges between two receptor chains. The asymmetric heparin binding involves contacts with both FGF1 molecules but only one receptor chain. The structure of the FGF1-FGFR2-heparin ternary complex provides a structural basis for the essential role of heparan sulfate in FGF signaling.
This datum is of extremely relevant if one considers that the relative amount of HS of Apert ECM is altered. 26 So strength is given to the idea that the wide range of clinical features in Apert syndrome can be related not only to the specific gene mutations but also to the spectrum of ECM and cytokines where the mutation acts. parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism. 31, 32 Cranial malformation depends on the order and rate or progression of sutural synostosis. Brachycephaly is the most commonly observed, but scaphocephaly and trigonocephaly also are described. 33 Shallow orbits is an essential diagnostic feature. Ocular proptosis is a consequence and results in a high frequency of conjunctivitis. Because of maxillary hypoplasia, the anteroposterior dimension of the dental arch is shortened and crowding teeth is common, as well as anterior open bite and mandibular overjet. 4 There is marked variability in both cranial and facial manifestations of the syndrome. Dodge et al 34 reported five patients, three with typical Crouzon syndrome. The other two patients had syndactylism of both hands and feet, and are more correctly said to have Vogt cephalodactyly. Vulliamy and Normandale 35 identified 14 cases of Crouzon disease in four generations of a family with several instances of male-to-male transmission. Juberg and Chambers 36 suggested, on the basis of an affected brother and sister with unaffected nonconsanguineous parents, that a recessive form of Crouzon disease exists. It seems more likely that they were dealing with a recessive form of craniosynostosis. Under the designation cranial dysostosis with pronounced digital impressions, or pseudo-Crouzon disease, Franceschetti 37 described a seemingly distinct disorder. There is not a general agreement if the pseudo-Crouzon syndrome is a separate entity.
Genes
Because of the clear importance of BEK expression in osteogenesis, 13 FGFR2 became a candidate gene for Crouzon syndrome. In 1994, Reardon et al 38 found single strand chain polymorphism (SSCP) variations in the B exon of FGFR2 in nine unrelated affected individuals, as well as complete cosegregation between SSCP variation and disease in three unrelated multigeneration families. In four sporadic cases, the unaffected parents did not have the SSCP variation. Direct sequencing revealed specific mutations in the B exon in all nine sporadic and familial cases, including replacement of a cysteine in an immunoglobulin-like domain in five patients. In only 9 of 20 patients with Crouzon syndrome did the authors find mutations in the FGFR2 gene. However, there was no evidence for genetic heterogeneity either in a previously published linkage report 39 or in the new data. It was thought likely that mutations in other areas of the FGFR2 gene were responsible for the cases yet to be explained. In addition, Jabs et al 40 demonstrated mutations in the FGFR2 gene in patients with Crouzon syndrome. Subsequently, Meyers et al 41 reported that the two related patients with Crouzon syndrome had different mutations: one had Crouzon syndrome caused by an FGFR2 ser347-to-cys mutation, whereas the second cousin had Crouzon syndrome with acanthosis nigricans caused by an FGFR3 ala391-to-glu mutation.
In 1995, Lajeunie et al 42 and Rutland et al 43 found mutations in the FGFR2 gene in some patients with Pfeiffer syndrome. In the instance of some mutations, the disorder was Pfeiffer syndrome in some families and Crouzon syndrome in others. Thus, mutations in the FGFR2 gene may result in any one of several different phenotypes. The clinical criteria of Pfeiffer syndrome, particularly interphalangeal ankylosis, are thought to be distinctive. There is no confusion of Pfeiffer syndrome with Crouzon syndrome, in which no hand anomalies and occasional radial-ulnar synostosis have been reported, or with Jackson-Weiss syndrome, which includes a tarsal-metatarsal coalescence and a medial deviation of broad great toes. Steinberger et al 44 described an FGFR2 mutation in a large family with autosomal dominant craniosynostosis with marked phenotypic variation and with clinical manifestations that were not classifiable as Apert, Crouzon, Pfeiffer, or Jackson-Weiss syndromes. The mutation detected in the family described by Steinberger et al is identical to that described in a family with Crouzon syndrome by Reardon et al 38 and by Jabs et al. 40 The occurrence of different phenotypes with the same mutation may reflect the presence on the same chromosome of a particular change elsewhere in the gene. We are reminded by Mulvihill 45 that in statistical parlance, some clinical diagnoses of syndromes of multiple malformations are more like confidence intervals than point estimates. He further suggests that ''permutation'' may be a better term than ''mutation.'' With more than 100 craniosynostosis syndromes, 9 FGFs, and 4 FGFRs for them, each with many overlapping and homologous regions, combination and permutation may lead to the inevitable failure of the one mutation-one disease model.
In a study of sporadic cases of Crouzon syndrome and Pfeiffer syndrome, Glaser et al 46 used four intragenic polymorphisms to screen a total of 41 families with Crouzon and Pfeiffer syndromes. Of these, 22 (11 for each syndrome) were informative. They found 11 different mutations in the 22 families. By molecular means, they proved that the origin of these different mutations was paternal in all informative cases analyzed. Advanced paternal age was noted for the fathers of patients with Crouzon syndrome or Pfeiffer syndrome, compared with the fathers of control APERT AND CROUZON SYNDROMES / Carinci et al individuals. The data extended previous information on advanced paternal age for sporadic FGFR2 mutations causing Apert syndrome and FGFR3 mutations causing achondroplasia.
In 2002, we performed 47 a genetic profile by DNA microarrays in patients with Apert or Crouzon syndromes. The experiment yielded different clusters of expressed sequence tags (ESTs). Expression profiles from craniosynostosis-derived fibroblasts differ from those of wild-type fibroblasts. Furthermore, two EST clusters discriminate the Crouzon from Apert fibroblasts. The differentially expressed genes cover a broad range of functional activities, including bone differentiation, cell-cycle regulation, apoptotic stimulation, and signaling transduction, cytoskeleton, and vesicular transport. So we conclude that the transcriptional program of craniosynostosis fibroblasts differs from that of wild-type fibroblasts, and moreover, the expression profiles of Crouzon and Apert fibroblasts can be distinguished by two EST expression clusters.
Cells and Extracellular Matrix
The complex and largely obscure regulatory processes that underline ossification and fusion of the sutures during skull morphogenesis are dependent on the conditions of the extracellular microenvironment. The concept that growth factors are involved in the pathophysiology of craniosynostosis caused by premature fusion of skull bone sutures is supported by genetic data. Crouzon and Apert syndromes are characterized by point mutations in the extracellular or transmembrane domains of FGFR2. However, the exact role of each single component of ECM in determining the phenotype of patients with Crouzon syndrome is not clear.
In 1996, Bodo et al 48 showed that Crouzon fibroblasts have an accelerated proliferation rate.
[3H]Glucosamine incorporation studies revealed that the various classes of glycosaminoglycans (GAG) secreted into the medium were differently distributed in Crouzon and normal fibroblasts. Crouzon fibroblasts secreted less total GAG, particularly HA and HS, but a relatively greater quantity of CS. Type I and III collagen were raised in Crouzon fibroblast medium, whereas the concentration of fibronectin was lower than in normal cells. IL treatment induced changes in cell growth and neosynthesis of extracellular matrix macromolecules. Both IL-1 and IL-6 stimulated proliferation of Crouzon fibroblasts, whereas only IL-6 increased stimulated normal cells. IL-1 provided a drop in HA and a rise in GAG sulphates in normal fibroblasts but caused an opposite effect in Crouzon fibroblasts. Type I collagen and fibronectin secretions are differently modulated by the cytokines in the two populations. Moreover, levels of IL-1 and of IL-1 receptor antagonist (IL-1ra) were higher in pathologic than in normal fibroblasts. Levels of IL-1 and IL-6 proteins also are enhanced in Crouzon fibroblasts.
Because coactivation of ILs and basic FGF probably is implicated in morphogenetic and osteogenic processes and heparan sulphate proteoglycans have a critical role in regulating bFGF activity, the phenotypes of normal and Crouzon osteoblasts were studied and the effects of bFGF on the expression of bFGF, procollagen alpha1 (I), and proteoglycan (PG) genes for biglycan, decorin, betaglycan, and syndecan were analyzed. 49 The basic FGF induced changes in the GAG profile and in the levels of PG and procollagen alpha1 (I) and downregulated heparan sulfate GAG chains. Moreover, bFGF-induced IL secretion differed in normal and Crouzon osteoblasts.
In 2000, Bodo et al 50 provided the evidence that fibroblasts obtained from patients affected by Crouzon syndrome retain their capacity to respond to bFGF. The growth factor reduces IL-1 secretion, downregulates biglycan and procollagen alpha, and increases betaglycan expression.
Baroni et al 51 analyzed the phenotype of cultured fibroblasts from normal subjects and from patients with Crouzon syndrome especially for TGFs and basic FGF. In Crouzon fibroblasts GAGs and fibronectin were decreased and type I collagen increased. TGF-B1, TGF-B3, and bFGF levels were lower in Crouzon than in normal cells. Adding bFGF increased TGF-B1 and TGF-b3 secretion, suggesting the drop is caused by the altered signal transduction of bFGF. A correlation between TGFs and bFGF was shown.
Finally, Bodo et al 52 analyzed the role of some FGF signalling molecules involved in FGFR2 regulation and their effects on the ECM. The authors studied the growth factor receptor-bound protein 2 (Grb2) tyrosine phosphorylation and the phosphotyrosine proteins associated with Grb2. Compared with normal fibroblasts, fibronectin synthesis was decreased in Crouzon fibroblasts, and protease activities in cells and medium were enhanced, suggesting that excess fibronectin catabolism is present. Differences were more marked when FGF2 was added. Very few phosphoproteins were visible in anti-Grb2 immunoprecipitations from Crouzon fibroblasts, which showed a significant increase in the number of highaffinity and low-affinity FGF2 receptors. These results suggest that the abnormal genotype and the Crouzon cellular phenotype are related. To compensate the low levels of tyrosine phosphorylation,
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Crouzon cells might increase the numbers of FGFR2, thus increasing the cell surface binding sites for FGF2.
CONCLUSION
A pert and Crouzon syndromes are well known craniostenoses. In the last 10 years, several studies have been done to provide a better comprehension of the etiology and pathogenesis of these syndromes.
Both have an autosomal dominant mode of transmission and a mutation in the gene encoding for the FGFR2 as the cause in most patients. However, the fact that the same mutation can result in a wide range of phenotypic expression makes the mechanism of anomalous development more complex.
ECM is composed of proteins, glycosaminoglycans, and cytokines that are secreted in an autocrine and paracrine manner and are able to modify the ECM. FGFs are complexed with heparan sulfate, a component of the ECM, before binding the FGFR2. Data exist about different expressions of cytokines and ECM macromolecules in craniostenosis-derived fibroblasts and osteoblasts. Changes in ECM composition could explain the altered osteogenic process and account for pathological variations in cranial development in addition to FGFR2 mutations.
